Clinical Trial Update: A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 trial evaluating tarextumab (OMP-59R5) in combination with nab-paclitaxel and gemcitabine in previously untreated stage IV pancreatic cancer; study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• tarextumab (tarextumab)

Snippet

Sponsor: OncoMed Pharmaceuticals, Inc. | Conditions: Stage IV Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-15